Consulting and advisory services
Expertise to navigate from molecule to medicine
When millions are at stake, the ability to navigate complex global requirements, trends and emerging issues is critical to your success.
ICON has over three decades of experience in advising clients, from molecule to medicine. Our asset development, regulatory affairs consulting and commercial consultants serve clients around the globe— delivering customized solutions to meet the needs of biotech startups, big pharma and medical device developers —as well as the research, investment and legal firms that serve them.
Advisory services and consulting across all phases of drug and device development
- Non clinical and Pre-clinical development Intelligent non-clinical design to expedite development and maximise clinical flexibility
- Due diligence and asset valuation Demonstrating potential of drug and device candidates.
- Value and evidence communication Strategies to communicate your product's value to key stakeholders
- Global pricing and market access strategy Expertise and integrated solutions to accelerate market access and drive product adoption
- Medical device consulting Dedicated medical device and diagnostics experts for all stages of development
- Regulatory strategy Helping clients to navigate complex global regulatory requirements and emerging issues.
Non clinical and Pre-clinical development
Intelligent non-clinical design to expedite development and maximise clinical flexibility
Due diligence and asset valuation
Demonstrating potential of drug and device candidates.
Value and evidence communication
Strategies to communicate your product's value to key stakeholders
Global pricing and market access strategy
Expertise and integrated solutions to accelerate market access and drive product adoption
Medical device consulting
Dedicated medical device and diagnostics experts for all stages of development
Regulatory strategy
Helping clients to navigate complex global regulatory requirements and emerging issues.
Regulatory Intelligence
It is essential to develop a regulatory strategy plan early in drug development to identify key challenges that may arise, and interact collaboratively with regulatory authorities.
.jpg?crop=yes&w=1430&h=750&a=5,0&itok=APM5W11r "11551-ICON-Pharmacovigilance-in-APAC-webinar_Homepage-banner-(2)"){kind=icon}
Managing safety reporting in the evolving regulatory environment of Asia Pacific
Watch on-demand webinar recording.
Resilient clinical trials: decentralising and digitising
Watch on-demand webinar recording.
ICON panel discussion features executive speakers from AstraZeneca, Otsuka, and Moderna.
Decentralised clinical trials
Alternative trial models which can include digital health technologies, in-home clinical visits and remote monitoring.
Digital Disruption
Technologies that accelerate and improve clinical trials.
HTA and market access implications for gene therapies
Watch on-demand webinar recording.
Adaptive Design Clinical Trials
An adaptive design clinical trial can help to create a stronger value proposition for your medical device by reducing development costs and accelerating time-to-market.
Real World Data
Late phase research, technology solutions and access to RWD are at the forefront of creating efficiencies in all stages of study design and implementation
The IVDR Journey
A roadmap to meet 2022 deadlines, while navigating pandemic disruptions
Our strategic advisory consultants provide complete end-to-end solutions across the entire life cycle of drug and device development:
Holistic, integrated approach
Digital and data analytics capabilities
Experienced professionals focused on your success
